AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2018
Oct 15, 2018
32254_dirs_2018-10-15_10a519b3-d3a6-411c-8996-272ba11e0f67.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2018-10-11
Reporting Person: ANDO GORAN (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-10-11 | Employee Stock Option (right to buy) | $3.06 | A | 15000 | Acquired | 2028-10-11 | Common Stock (15000) | Direct |
Footnotes
F1: The option becomes exercisable in three equal annual installments beginning on October 11, 2019.
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Apr 13
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7